Adafosbuvir is an investigational nucleotide analogue currently being studied as a direct-acting antiviral agent for the treatment of hepatitis C virus (HCV) infection. By acting as a prodrug that inhibits… Read more
Adafosbuvir is an investigational nucleotide analogue currently being studied as a direct-acting antiviral agent for the treatment of hepatitis C virus (HCV) infection. By acting as a prodrug that inhibits the viral NS5B RNA-dependent RNA polymerase, it interferes with viral genome replication. To support the rigorous analytical demands of drug development, this category provides a comprehensive range of Adafosbuvir reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These materials are essential tools for pharmaceutical laboratories, facilitating precise impurity profiling, stability studies, and method validation. By serving as reliable benchmarks, these high-quality standards enable scientists to accurately identify and quantify trace-level substances, ensuring the integrity, safety, and regulatory compliance of the drug substance throughout the manufacturing process and lifecycle of the therapeutic candidate.